New Data Shows Oral GLP-1 Drug Effective for Weight Loss in Women Across All Menopausal Stages
A post hoc analysis of two major clinical trials indicates that orforglipron, an oral non-peptide GLP-1 receptor agonist, produces significant weight loss in women with obesity regardless of their menopausal status. Presented at the European Association for the Study of Diabetes (EASD) 2026 in Milan, the findings suggest the drug’s efficacy remains consistent whether patients are premenopausal, perimenopausal, or postmenopausal. In the ATTAIN-1 trial, which excluded patients with diabetes, women lost between 12.81% and 14.38% of their body weight on the 36 mg dose, compared to less than 1.02% on placebo. Similarly, in ATTAIN-2, which included patients with type 2 diabetes, weight loss ranged from 8.88% to 13.62% depending on menopausal stage. Over 80% of women in the non-diabetic trial achieved at least a 5% weight reduction, a figure far higher than the 20-25% seen in the placebo group. The study also noted improvements in waist-to-height ratios across most subgroups. While the results highlight broad applicability for women across different life stages, the analysis was supported by Eli Lilly, the manufacturer of orforglipron, and all authors were company employees.
